NEW YORK (GenomeWeb) – Qiagen has extended the offer period for its DKK683 million ($103.5 million) acquisition of Exiqon. It announced in late March a voluntary conditional public takeover offer to buy all of Exiqon's shares for DKK18 per share, and as of the end of the day on May 18 had received acceptances from shareholders in Exiqon representing around 81 percent of the share capital and voting rights in the firm. Qiagen said the offer now expires at the end of the day on June 2.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Human Longevity alleges that Craig Venter stole trade secrets in a lawsuit filed against the J. Craig Venter Institute.

A new paper critiques the analysis and conclusions of the Atacama mummy genome sequencing study.

In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.

An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.